The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK made a $300 million dollar deal with 23andMe which allowed it to acquire the genetic data of 5 million people. That means the value of each customer’s data was about $60 at that time.

The fall of 23andMe raises privacy concerns as Regeneron buys its genetic database for $256M after bankruptcy.

It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly handed over the samples to completely different owners.

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% rise in 3 years.

Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles including a data breach.

Thank you for your interest in Regeneron and welcome to our first quarter 2025 earnings conference call. An archive and transcript of this call will be available on Regeneron's Investor Relations ...

Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more.

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Neutral to Buy. Analyst Price Forecast Suggests 44.26% Upside As of May 6, 2025,